Praxis Precision Medicines Reveals POWER1 Study Outcomes for Focal Onset Seizures
Praxis Precision Medicines (PRAX) has released the findings from its Phase 2/3 POWER1 study, evaluating vormatrigine for focal onset seizures. While primary efficacy goals were not fully met, the study demonstrated positive effectiveness in higher doses, alongside a favorable safety profile and low patient discontinuation rates. The company plans to leverage these insights for future drug development and remains committed to commercializing other key therapies.
By Mr. Money Mustache